MYADM

Myeloid-associated differentiation marker · Q96S97 · MYADM on Sugi Atlas →

0 patent compounds predicted against MYADM, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MYADM by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Centocor Microarray Study of Patients PHASE4COMPLETED
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia PHASE2COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia PHASE1/PHASE2COMPLETED
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML PHASE1/PHASE2COMPLETED
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia PHASE2COMPLETED
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers PHASE2COMPLETED
IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN PHASE2COMPLETED
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms PHASE1/PHASE2RECRUITING
Expression of Aberrant CD Markers in Acute Leukemia:Retrospective Study in South Egypt Cancer Institute nanUNKNOWN
Postprandial Monocyte Study nanCOMPLETED
Kinetics of INF-γ Production in Intensive Care Patients nanRECRUITING
Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response nanCOMPLETED
Detection of Circulating Biomarkers of Immunogenic Cell Death nanCOMPLETED
Prognostic Value of CD318 in AML at Assiut University Hospital. nanUNKNOWN
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Study of Trans-tissular Migration of Macrophages Associated to Human Breast Cancer nanUNKNOWN
Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches nanACTIVE_NOT_RECRUITING
Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM) nanRECRUITING
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia nanUNKNOWN
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia nanUNKNOWN
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes nanCOMPLETED
S9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab Ozogamicin nanCOMPLETED
Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) nanWITHDRAWN
Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes. nanUNKNOWN
Monocyte Phenotypic Changes in Heart Failure nanCOMPLETED
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition. nanRECRUITING
The Myeloid Neoplasms Biology and Outcome Project nanRECRUITING
Pilot Study to Establish a Repertoire of Megakaryocyte Markers, Quantifiable by Spectral Flow Cytometry, in Bone Marrow and Circulating in Patients Undergoing Cardiac Surgery for Bypass Grafting nanNOT_YET_RECRUITING
A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia nanRECRUITING
Immunophenotyping and Xist Gene in AML nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MYADM binder may also engage these)

ProteinNameSimilarity
Q5R6H1 1.000 Q5R6H1 →
Q6VBQ5 0.980 Q6VBQ5 →
MAL2 Protein MAL2 0.977 landscape →
A2VE13 0.976 A2VE13 →
O35682 0.975 O35682 →
Q5RAI2 0.972 Q5RAI2 →
Q8BI08 0.966 Q8BI08 →
O09198 0.961 O09198 →
Q64349 0.960 Q64349 →
Q3ZBY0 0.960 Q3ZBY0 →
Q9ESD6 0.958 Q9ESD6 →
Q96FZ5 0.958 Q96FZ5 →
Q5VXT5 0.958 Q5VXT5 →
Q95MN6 0.954 Q95MN6 →
Q6Y1E2 0.952 Q6Y1E2 →
Q6GPN9 0.951 Q6GPN9 →
O89104 0.951 O89104 →
Q9QZE9 0.948 Q9QZE9 →
Q28296 0.948 Q28296 →
Q9JMG4 0.947 Q9JMG4 →
Q66IV3 0.947 Q66IV3 →
Q3URJ8 0.947 Q3URJ8 →
O62646 0.947 O62646 →
Q6UX01 0.947 Q6UX01 →
Q8N8D7 0.947 Q8N8D7 →
Q4R7X9 0.947 Q4R7X9 →
A4K2N5 0.946 A4K2N5 →
Q8N2H4 0.946 Q8N2H4 →
Q78S06 0.946 Q78S06 →
Q32NX4 0.946 Q32NX4 →